New Study: HPV Vaccine Linked to Zero Cervical Cancer Deaths in Young Women

A new study published in The Lancet highlights the significant impact of the HPV vaccine on reducing deaths from cervical cancer.

The research tracked cervical cancer deaths in England between 2001 and 2024. In the 20-24 age group, where 90 percent of women had received the vaccine, there were no reported deaths from cervical cancer over a five-year period. Most women in this youngest group were vaccinated around ages 12 or 13.

Lead researcher Peter Sasieni described the findings as "eye-opening," stating he did not expect to see zero deaths for five consecutive years. He emphasized the vaccine's substantial public health benefits.

The study also observed a notable reduction in cancer risks and deaths for the 25-29 age group. The oldest cohort, aged 30-34, had less access to or awareness of the vaccine, resulting in a smaller decrease in mortality compared to younger groups. Sasieni estimated that cervical cancer deaths have been reduced by at least 80 percent.

While the results are highly encouraging, Sasieni cautioned that the study is observational. He noted that a few deaths might still appear as 2025 data becomes available, but affirmed the undeniable public health significance of the vaccine.